Source: Siyu MedTech; Editor: Qi Yuan
Reprint Requirements: Please indicate the source of the article at the beginning of the text, and it can be reprinted directly.
February 24,Boston Scientific and Shulan (Boao) Hospital Reach Strategic Cooperation, and witnessed by Academician Shusen Zheng of the Chinese Academy of Engineering, Academician Lanjuan Li of the Chinese Academy of Engineering, Academician Gaojun Teng of the Chinese Academy of Sciences, Yuzhang Wang, Chairman of the China Foundation for Hepatitis Prevention and Control, Dabiao, Vice President of Boston Scientific Corporation, etc.,Establishment and ListingYttrium-90 Liver Cancer Innovative Treatment Center, marking another milestone in the 2.0 cooperation between Boston Scientific and Lecheng Pilot Zone.
Shulan (Boao) Hospital Officially Unveiled in Hainan's Lecheng Pilot Zone
Boston Scientific China Vice President Dabo Attends Pharmaceutical Enterprise Cooperation Launch Ceremony
As a country with a high incidence of liver cancer, China's liver cancer incidence and mortality rates remain persistently high, with numerous cases in China.70%~80%Patients who are not eligible for surgical resection at the time of initial treatment[1], Patients with liver cancerThe five-year overall survival rate is only 14.1%.[2]. In the face of inoperable liver cancer,Yttrium-90 Glass Microspheres (hereinafter referred to as "Y90 Glass Microspheres")Has become a clinical treatment method with both the advantages of precise minimally invasive intervention and accurate nuclear medicine diagnosis and treatment.Lecheng Pilot Zone is currentlyThe Only "Medical Special Zone" in ChinaBoston Scientific seized the policy and platform opportunities in Lecheng. As early as May 2022, the first Y90 glass microsphere treatment "pilot" surgery in China was successfully completed in Lecheng, marking the beginning of a 2.0 era of cooperation between the two parties.The launch of the Yttrium-90 Liver Cancer Innovative Treatment Center through the collaboration between Boston Scientific and Shulan (Boao) Hospital will further accelerate the clinical application of Y90 glass microspheres in Hainan, promoting significant advancements in liver cancer treatment and services in China.# What is Yttrium-90 Microsphere Therapy
Yttrium-90 microsphere therapy first appeared in 1998 and was developed by a local pharmaceutical company in Australia as a new treatment method.The main principle is brachytherapy.. Approved by the U.S. FDA for colorectal cancer liver metastasis in 2002, and by the EU for unresectable liver cancer patients in 2003. Currently, this technology is available globallyMore than 50 countries and regionsUse, AccumulatedUsed by more than 120,000 people, both safety and efficacy have been fully validated.
Although Yttrium-90 microsphere therapy has been available for more than 20 years, it has only recently been introduced in China.In 2022, the first Yttrium-90 microsphere therapy in China was successfully carried out in Hainan.Yttrium-90 microsphere therapy is a type of selective internal radiation therapy, which is a form of precision radiotherapy and also a minimally invasive treatment. During the procedure, millions of glass microspheres containing the radioactive substance Yttrium-90 are injected into the blood vessels that nourish liver tumors, allowing the microspheres to precisely enter the interior of the liver tumor. The beta rays they emit can kill cancer cells at close range within the liver.This therapy is suitable for patients with malignant liver cancer who cannot undergo resection/unwilling to accept surgical resection or ablation treatment., such as hepatocellular carcinoma, metastatic liver cancer, and cholangiocarcinoma, etc. Patients who do not respond well to hepatic artery embolization or hepatic artery infusion can also be treated with Yttrium-90 microsphere therapy.For more details, see the expert consensus: https://mp.weixin.qq.com/s/RazP6BL1sENkO5TZ_iNJhgDabo, Vice President of Boston Scientific China"Y90 glass microspheres have been on the market abroad for over 20 years, accumulating more than 100,000 clinical cases and supported by strong clinical data. This collaboration with Shulan Healthcare, an outstanding representative of the local medical ecosystem, makes me highly optimistic about the future of the Y90 liver cancer innovation treatment center. Currently, Y90 glass microspheres are accelerating the process of local registration and commercialization in China. With the support of all experts, I believe this excellent product will soon expand from Boao to the rest of China, allowing more Chinese liver cancer patients to benefit from the advanced Y90 therapy!"[1] Liu Ming, et al. Expert Consensus on Image-Guided Cryoablation for Liver Cancer (2020 Edition). Chinese Journal of Medicine[J]. 2020, 55(5): 489-492.
[2] Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J].Lancet, 2018, 391(10125): 1023-1075.
Global MedTech TOP100: 2023 Global MedTech TOP100
2023 Global MedTech Industry Contribution Award
2023 Global Medical Technology Innovation Award
2023 Global MedTech Rising Star Award
2023 Global Innovative Medical Device Award
Global Leading Medical Device Companies | Dynamic CollectionChina Medical Device Listed Companies | Dynamic CollectionMindray Medical|JIUAN Medical|Weigao Group|DAAN Gene|Lepu Medical|Mingde Biotech |Xinhua Medical|United Imaging Healthcare|Oriental Biotech|Yuwell Medical|Kehua Bio-engineering|Intco Medical|SaintDiagnostics|Guo Ke Heng Tai|DAAN Gene|Ying Tai Medical
Editor-in-Chief | Zhao Qing Reviewed by | Yi He
